Healthcare is one of the most reliable sectors for dividend income — and Johnson & Johnson and AbbVie are the two names that appear in nearly every income investor's portfolio conversation. Both yield attractively. Both have strong dividend track records. Both are large, well-known pharmaceutical companies.
But treating them as interchangeable is a mistake. Their business models, their patent exposure, and their dividend histories are fundamentally different — and the Weiss method treats them differently because of it.
JNJ: The Diversified Healthcare Conglomerate
Johnson & Johnson (JNJ) has raised its dividend for over 62 consecutive years — one of the longest streaks of any stock on DividendVisual. Through product recalls, opioid litigation, patent cliffs, and the 2023 spinoff of its consumer health division (Kenvue), JNJ has never missed a dividend raise.
Post-spinoff, JNJ is now a focused pharmaceutical and medical device company. The consumer brands — Band-Aid, Tylenol, Neutrogena — belong to Kenvue. What remains is higher-margin, more patent-protected, and arguably more durable for the next decade of dividend growth.
The key JNJ risk for income investors is patent concentration. The oncology portfolio — particularly Darzalex and Carvykti — is growing fast, but patent cliffs on aging drugs are a recurring challenge in pharma. JNJ has historically navigated these well through R&D and acquisitions, but it's always the background risk.
The payout ratio for JNJ has typically run 40–55% of earnings, conservative for a pharma company. Free cash flow coverage is strong. The quality score reflects this: JNJ consistently rates Excellent or Good by DividendVisual's model.
AbbVie: High Yield, High Growth, Higher Risk
AbbVie (ABBV) was spun off from Abbott Laboratories in 2013. It inherited the Humira franchise — one of the best-selling drugs in pharmaceutical history — and has spent the decade since managing the inevitable biosimilar competition that hits blockbuster biologics when patents expire.
Humira's US patent protection expired in 2023, and biosimilar competition has been intensifying. AbbVie anticipated this: the acquisitions of Allergan (2020) and the buildup of Skyrizi and Rinvoq as successor immunology drugs have been specifically designed to offset Humira erosion. Early indications suggest the transition is working — Skyrizi and Rinvoq revenue has grown faster than Humira has declined.
ABBV's dividend is younger than JNJ's by decades. As an Abbott spinoff, ABBV's independent track record starts in 2013. The consecutive raise streak is meaningful but shorter. The payout ratio is higher — often running 60–80% of GAAP earnings, though adjusted for non-cash amortization of acquired assets, the coverage looks better.
The yield is structurally higher than JNJ's. ABBV has typically yielded 3.5–5%+ — a premium that reflects both the perceived execution risk on the post-Humira transition and the stock's lower valuation multiple. For income investors, this means more current income and more price volatility.
The Yield History Divergence
This is where the Weiss comparison becomes concrete.
JNJ's 10-year yield range has historically been tight and well-behaved — roughly 2.3% to 3.5%, with a median around 2.7–2.9%. The tightness reflects JNJ's stability premium: investors rarely panic-sell a company with 60+ years of consecutive dividend growth. Weiss undervalue signals on JNJ are meaningful precisely because they're uncommon — when JNJ yields 3.2%+, something unusual is happening.
ABBV's yield range is wider and structurally higher — roughly 3.2% to 6%+, with the upper extreme reached when Humira patent concerns peaked. The median sits around 4.0–4.5%. Because ABBV is perceived as carrying more execution risk, it always commands a yield premium over JNJ — even when the dividend is equally well-covered.
The practical implication: JNJ is a lower-yield, lower-volatility income holding. ABBV is a higher-yield, higher-volatility income holding. The Weiss method evaluates each against its own history — it doesn't compare them to each other.
What the Quality Scores Reflect
DividendVisual's quality score penalizes shorter dividend streaks and higher payout ratios. JNJ's 62-year streak earns maximum points on the streak factor. ABBV's shorter independent history (13 years post-spinoff) earns fewer streak points, even though Abbott's pre-spinoff streak was much longer.
This is a known limitation of any streak-based model applied to spinoffs. In practice, AbbVie inherited a culture of dividend growth from Abbott and has maintained it without interruption. Investors can reasonably treat the pre-spinoff Abbott history as relevant context — just not as a guarantee.
Check the current signals:
Which to Hold?
These stocks serve different functions in a portfolio.
JNJ is an anchor position — lower yield, lower drama, 62 consecutive raises. It belongs in any dividend portfolio as a bedrock holding. The question is never "should I own JNJ?" but "is the current entry price historically attractive?"
ABBV is a higher-conviction income position — more yield, more execution risk, more dependence on the Skyrizi/Rinvoq ramp succeeding. It rewards investors who did the work to understand the post-Humira transition and were comfortable with the volatility during peak uncertainty.
Holding both in different weights is a reasonable approach: JNJ as the stable base, ABBV as the higher-yield complement. The Weiss signals will tell you which is offering a better entry at any given time.
Both belong to the Dividend Aristocrats collection tracked on DividendVisual.
This article is for informational purposes only and does not constitute financial advice. Pharmaceutical companies carry drug-specific risks not captured by yield history alone. Verify current patent timelines and pipeline status before investing.